Last reviewed · How we verify

NCT06925828

Application of in Vivo Splitting Technique in Adult Liver Transplantation

Active, enrolled Last updated 13 April 2025
What this trial tests

trial testing No intervention in Liver Transplantation in 500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 January 2021
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorNingbo Medical Center Lihuili Hospital
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment500
Start date1 January 2021
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Ningbo Medical Center Lihuili Hospital

Who can join

Adults 16 to 75, any sex, with Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The feasibility of split liver transplantation (SLT) remains controversial. This study aimed to evaluate the outcomes of SLT in adult recipients and to identify specific areas of improvements. A retrospective analysis was conducted on adults who underwent full size SLT between January 2021 and December 2023. The short-term outcomes of these patients who underwent SLT were compared with those of patients who underwent whole liver transplantation (WLT) during the same period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Liver Transplantation

Currently open trials in the same condition.

Other Ningbo Medical Center Lihuili Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06925828.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing